These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 12392638)

  • 1. Management of gastrointestinal stromal tumors in the era of tyrosine kinase inhibitors.
    George S; Desai J
    Curr Treat Options Oncol; 2002 Dec; 3(6):489-96. PubMed ID: 12392638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
    Demetri GD
    Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastrointestinal stromal tumors: chemotherapy and imatinib.
    Muler JH; Baker L; Zalupski MM
    Curr Oncol Rep; 2002 Nov; 4(6):499-503. PubMed ID: 12354362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
    Gold JS; Dematteo RP
    Ann Surg; 2006 Aug; 244(2):176-84. PubMed ID: 16858179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastrointestinal stromal tumors: rationale for surgical adjuvant trials with imatinib.
    Cormier JN; Patel SR; Pisters PW
    Curr Oncol Rep; 2002 Nov; 4(6):504-9. PubMed ID: 12354363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options.
    Demetri GD
    Semin Oncol; 2001 Oct; 28(5 Suppl 17):19-26. PubMed ID: 11740803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced gastrointestinal stromal tumors successfully treated with imatinib mesylate: a report of two cases.
    Hasan S; Hassan M; Oke L; Dinh K; Onojobi G; Lombardo F; Dawkins F; Jack M
    J Natl Med Assoc; 2003 Dec; 95(12):1208-10. PubMed ID: 14717479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Surgical treatment of gastrointestinal stromal tumors: personal cases].
    Schirru A; Cavaliere D; Cosce U; Scarimbolo M; Griseri G; Caristo I; Bianchi M; Ingravaglieri E; Aiello D; Venturino E
    Tumori; 2003; 89(4 Suppl):141-2. PubMed ID: 12903574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The GIST of targeted cancer therapy: a tumor (gastrointestinal stromal tumor), a mutated gene (c-kit), and a molecular inhibitor (STI571).
    DeMatteo RP
    Ann Surg Oncol; 2002 Nov; 9(9):831-9. PubMed ID: 12417503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function.
    Bauer S; Hagen V; Pielken HJ; Bojko P; Seeber S; Schütte J
    Anticancer Drugs; 2002 Sep; 13(8):847-9. PubMed ID: 12394270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of malignant gastrointestinal stromal tumours.
    Joensuu H; Fletcher C; Dimitrijevic S; Silberman S; Roberts P; Demetri G
    Lancet Oncol; 2002 Nov; 3(11):655-64. PubMed ID: 12424067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
    Wu PC; Langerman A; Ryan CW; Hart J; Swiger S; Posner MC
    Surgery; 2003 Oct; 134(4):656-65; discussion 665-6. PubMed ID: 14605627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer treatment. New drugs, new hope.
    Harv Health Lett; 2001 Jul; 26(9):1-3. PubMed ID: 11511447
    [No Abstract]   [Full Text] [Related]  

  • 18. [Gastrointestinal stromal tumor (GIST)--tyrosine kinase inhibitors].
    Nishida T; Yoshidome K; Tori M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():452-6. PubMed ID: 23513883
    [No Abstract]   [Full Text] [Related]  

  • 19. Imatinib mesylate: a molecularly targeted therapy for gastrointestinal stromal tumors.
    Eisenberg BL
    Oncology (Williston Park); 2003 Nov; 17(11):1615-20; discussion 1620, 1623, 1626 passim. PubMed ID: 14682111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?
    Scaife CL; Hunt KK; Patel SR; Benjamin RS; Burgess MA; Chen LL; Trent J; Raymond AK; Cormier JN; Pisters PW; Pollock RE; Feig BW
    Am J Surg; 2003 Dec; 186(6):665-9. PubMed ID: 14672776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.